Literature DB >> 16788140

Renal vascular endothelial growth factor in neonatal obstructive nephropathy. I. Endogenous VEGF.

Laura E Burt1, Michael S Forbes, Barbara A Thornhill, Susan C Kiley, Robert L Chevalier.   

Abstract

Obstructive nephropathy constitutes a major cause of renal impairment in children. Chronic unilateral ureteral obstruction (UUO) impairs maturation of the developing kidney and leads to tubular apoptosis and interstitial inflammation. Vascular endothelial growth factor (VEGF) is involved in recovery from various forms of renal injury. We questioned whether the renal expression of endogenous VEGF and its receptor (VEGFR2/Flk-1) is modified by UUO in early development. Neonatal rats were subjected to partial or complete UUO or sham operation. The distribution of immunoreactive VEGF in each kidney was examined after 7, 14, or 28 days. Adult rats were also subjected to sham operation or complete UUO. Tubular VEGF increased between 14 and 28 days in sham-operated rats and in some partially obstructed neonatal rats but decreased with complete UUO. Parallel changes were found by Western blotting, but not by RT-PCR. Immunoreactive VEGF colocalized with mitochondria in proximal and distal tubules and also appeared in type A intercalated cells, glomerular vascular endothelium, and podocytes. While neonatal microvascular renal VEGFR2 receptor staining was strongly positive regardless of UUO, staining was weak in sham-operated adults but increased following UUO. Parallel changes in VEGFR2 expression were verified by RT-PCR and Western blotting. We conclude that endogenous renal VEGF is developmentally regulated in the neonatal rat and is differentially regulated by partial and complete UUO. Following UUO in the adult, the VEGF receptor is upregulated. Endogenous VEGF may serve an adaptive role in responding to tubular injury caused by UUO and may modulate adaptation by the contralateral kidney.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788140     DOI: 10.1152/ajprenal.00293.2005

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  7 in total

1.  Inducible nitric oxide synthase modulates hydronephrosis following partial or complete unilateral ureteral obstruction in the neonatal mouse.

Authors:  Kee Hwan Yoo; Barbara A Thornhill; Michael S Forbes; Robert L Chevalier
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-04

2.  VEGF ameliorates tubulointerstitial fibrosis in unilateral ureteral obstruction mice via inhibition of epithelial-mesenchymal transition.

Authors:  Yao-guo Lian; Qiu-gen Zhou; Ying-juan Zhang; Fa-lei Zheng
Journal:  Acta Pharmacol Sin       Date:  2011-10-10       Impact factor: 6.150

Review 3.  Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease.

Authors:  Yujiro Kida; Bie Nga Tchao; Ikuyo Yamaguchi
Journal:  Pediatr Nephrol       Date:  2013-03-10       Impact factor: 3.714

Review 4.  Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy.

Authors:  Robert L Chevalier; Barbara A Thornhill; Michael S Forbes; Susan C Kiley
Journal:  Pediatr Nephrol       Date:  2009-10-21       Impact factor: 3.714

5.  Ethanol extract of gardenia fruit alleviates renal interstitial fibrosis induced by unilateral ureteral obstruction in rats.

Authors:  Xiaobo Li; Min Ma; Xianggui Zhang; Liang Deng; Yarong Wang; Zhuang Bian; Shining Cai; Bangya Peng; Jiangquan Yang; Yang Chen
Journal:  Exp Ther Med       Date:  2017-06-23       Impact factor: 2.447

Review 6.  The molecular biology of pelvi-ureteric junction obstruction.

Authors:  Laura Jackson; Mark Woodward; Richard J Coward
Journal:  Pediatr Nephrol       Date:  2017-03-13       Impact factor: 3.714

7.  LTBP4 affects renal fibrosis by influencing angiogenesis and altering mitochondrial structure.

Authors:  Chi-Ting Su; Tzu-Ming Jao; Zsolt Urban; Yue-Jhu Huang; Daniel H W See; Yao-Chou Tsai; Wei-Chou Lin; Jenq-Wen Huang
Journal:  Cell Death Dis       Date:  2021-10-13       Impact factor: 9.685

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.